natgillin/translations-raw huggingface dataset:
Pharmacotherapeutic group: antiepileptics, other antiepileptics ATC code: N03AX14. 
Farmakoterapijska skupina: antiepileptici, ostali antiepileptici, ATK oznaka: N03AX14.
Therefore, the interaction of Levetiracetam with other substances, or vice versa, is unlikely. 
Iz toga proizlazi da interakcija Levetiracetama s drugim tvarima, i obrnuto, nije vjerojatna.
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000). 
Nuspojave su prikazane u padajućem nizu s obzirom na ozbiljnost i njihova učestalost je definirana na sljedeći način: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000) i vrlo rijetko (<1/10 000).
How to store Levetiracetam Accord Contents of the pack and other information 
Kako čuvati Levetiracetam Accord Sadržaj pakiranja i druge informacije
What Levetiracetam Accord is and what it is used for What you need to know before you take Levetiracetam Accord How to take Levetiracetam Accord Possible side effects 
Što je Levetiracetam Accord i za što se koristi Što morate znati prije nego počnete uzimati Levetiracetam Accord Kako uzimati Levetiracetam Accord Moguće nuspojave
Levetiracetam Accord is an antiepileptic medicine (a medicine used to treat seizures in epilepsy). 
Levetiracetam Accord jest antiepileptik (lijek koji se koristi u liječenju epileptičkih napadaja).
Creatinine clearance (ml/min/1.73m2) 
Klirens kreatinina (ml/min/1,73m2)
Prevalence is significantly higher in Japanese patients when compared to nonJapanese patients. 
Prevalencija je značajno veća u japanskih bolesnika u usporedbi s bolesnicima koji nisu japanskog podrijetla.
What you need to know before you take Levetiracetam Accord 
Što morate znati prije nego počnete uzimati Levetiracetam Accord
Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73m2. 
Stoga se preporučuje 50%-tno smanjenje dnevne doze održavanja ako je klirens kreatinina < 60 ml/min/1,73 m2.
Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents including levetiracetam. 
Samoubojstvo, pokušaj samoubojstva te samoubilačke ideje i ponašanje bili su prijavljivani kod bolesnika liječenih antiepileptičkim lijekovima uključujući levetiracetam.
Should your doctor decide to stop your Levetiracetam Accord treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Accord. 
Ako Vaš liječnik odluči prekinuti liječenje Levetiracetam Accordom, uputit će Vas kako postupno prekinuti liječenje Levetiracetam Accordom.
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1. 
Preosjetljivost na djelatnu tvar ili neke druge pirolidonske derivae ili neku od pomoćnih tvari navedenih u dijelu 6.1.
This medicinal product does not require any special storage conditions. 
- Ovaj lijek ne zahtijeva posebne uvjete čuvanja.
Levetiracetam is indicated as adjunctive therapy 
Levetiracetam je indiciran kao dodatna terapija
In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69). 
U studiji, koja je bila odraz kliničke prakse bilo je moguće prekinuti istodobno antiepileptičko liječenje u ograničenog broja bolesnika koji su odgovorili na dodatno liječenje levetiracetamom (36 od 69 odraslih bolesnika).
It is therefore recommended to adjust the maintenance daily dose of levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2). 
Stoga se preporučuje prilagođavanje dnevne doze održavanja Levetiracetama s obzirom na klirens kreatinina u bolesnika s umjerenim i teškim oštećenjem bubrega (vidjeti dio 4.2).
The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg). 
Farmakokinetički podaci ukazuju da je poluvijek života (5,3 h) kraći nego u odraslih (7,2 h), a prividni klirens (1,5 ml/min/kg) brži je nego u odraslih (0,96 ml/min/kg).
Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviuor as measured in a standardised and systematic way using a validated instrument (CBCL - Achenbach Child Behavior Checklist). 
Rezultati ocjene funkcioniranja ponašanja i emocionalnog funkcioniranja uputili su na pogoršanje u smislu agresivnijeg ponašanja u skupini koja je uzimala levetiracetam, ocijenjenog na standardiziran i sistematičan način koristeći validirani instrument (CBCL - Achenbach Child Behavior Checklist).
Alopecia,eczema, pruritus, 
Alopecija, ekcem, pruritis,
500 to 1, 500 mg twice daily 500 to 1,000 mg twice daily 250 to 750 mg twice daily 250 to 500 mg twice daily 500 to 1,000 mg once daily (2) 
500 do 1500 mg dva puta na dan 500 do 1000 mg dva puta na dan 250 do 750 mg dva puta na dan 250 do 500 mg dva puta na dan 500 do 1000 mg jedanput na dan (2)
• severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke's oedema [swelling of the face, lips, tongue and throat]); 
• tjelesne težine alergijske reakcije (DRESS, anafilaktička reakcija [teška i ozbiljna alergijska reakcija], angioedem [oticanje lica, usana, jezika i grla];
The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. 
Početna doza za dijete ili adolescenta od 25 kg treba biti 250 mg dva puta na dan uz maksimalnu dozu od 750 mg dva puta na dan.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranicama Europske agencije za lijekove http://www.ema.europa.eu.
Do not use this medicine after the expiry date which is stated on carton box and blister after EXP. 
- Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake Rok valjanosti i „EXP”.
Other medicines and Levetiracetam Accord Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
Marketing authorization holder and manufacturer Marketing authorization holder Accord Healthcare S.L.U. 
Nositelj odobrenja za stavljanje lijeka u promet i proizvođač: Nositelj odobrenja za stavljanje lijeka u promet Accord Healthcare S.L.U.
However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline. 
Međutim, u ispitanika koji su uzimali levetiracetam tijekom dugoročne, otvorene studije provedene praćenjem, u prosjeku nije bilo pogoršanja bihevioralnog i emocionalnog funkcioniranja; osobito nije bilo pogoršanja pokazatelja agresivnog ponašanja u odnosu na početno stanje.
What Levetiracetam Accord looks like and contents of the pack 250 mg: 
Kako Levetiracetam Accord izgleda i sadržaj pakiranja 250 mg:
If you stop taking Levetiracetam Accord 
Ako prestanete uzimati Levetiracetam Accord
At 3600 mg /kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. 
Pri dozi od 3600 mg/kg/dan samo je u jednoj od dvije EFD studije uočeno blago smanjenje fetalne težine povezano s marginalnim porastom varijacija kostura/malih anomalija.
In both population pharmacokinetic analyses, there was about a 20% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product. 
U obje farmakokinetičke analize populacije prividni klirens levetiracetama se povećao za oko 20% kada se lijek davao istodobno s antiepileptikom koji inducira enzime.
Adverse reactions reported in clinical studies (adults, adolescents, children and infants> 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. 
Nuspojave zabilježene tijekom kliničkih studija (odrasli, adolescenti, djeca i dojenčad starija od 1 mjeseca) ili iskustva nakon stavljanja lijeka u promet navedene su u sljedećoj tablici s obzirom na organski sustav i učestalost.
CLcr (ml/min) CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73 BSA subject (m2) 
CLcr (ml/min) CLcr (ml/min/1,73 m2) = ------------------------------ x 1,73 PT bolesnika (m2)
In all of the above cases levetiracetam oral solution should be used. 
U svim tim slučajevima treba upotrijebiti oralnu otopinu levetiracetama.
Contains sunset yellow (E110). 
Sadrži sunset yellow (E 110).
10 film-coated tablets 20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 60 film-coated tablets 100 film-coated tablets 200 film-coated tablets 30 X 1 film-coated tablet 60 X 1 film-coated tablet 100 X 1 film-coated tablet 
10filmom obloženih tableta 20 filmom obloženih tableta 30 filmom obloženih tableta 50 filmom obloženih tableta 60 filmom obloženih tableta 100 filmom obloženih tableta 200 filmom obloženih tableta 30 X 1 filmom obloženih tableta 60 X 1 filmom obloženih tableta 100 X 1 filmom obloženih tableta
• skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (StevensJohnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis). 
• crvenilo kože koje može tvoriti mjehuriće i izgledati kao male mete (sa središnjim tamnim točkama okruženim bljeđim područjem i tamnim prstenom oko ruba) (erythema multiforme), jako rasprostranjen osip s mjehurma i kožom koja se ljušti, osobito oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom), i mnogo teži oblik koji uzrokuje ljuštenje kože na više od 30% površine tijela (toksična epidermalna nekroliza).
You should not drive or use machines until it is established that your ability to perform such activities is not affected. 
Ne smijete voziti ili upravljati strojevima dok se ne utvrdi da uzimanje lijeka Levetiracetam Accord ne utječe na Vaše sposobnosti za to.
Height (cm) x ks CLcr (ml/min/1.73 m2) = ----------------------------------Serum Creatinine (mg/dl) 
Visina (cm) x ks CLcr (ml/min/1,73 m2) = --------------------------------------kreatinin u serumu (mg/dl)
Film-coated tablet The tablet can be divided into equal halves 
Tableta se može razdijeliti u jednake polovice.
Excipient with known effect: Each film-coated tablet contains 0.013 mg of sunset yellow FCF (E110) 
Pomoćna tvar s poznatim učinkom: Jedna filmom obložena tableta sadrži 0,013 mg bojila sunset yellow FCF (E110).
The other strengths of Levetiracetam tablets do not contain this ingredient. 
Levetiracetam tableta me sadrže ovaj sastojak.
Additionally, the tablets are also available in unit dose blister for the pack size of 30x1, 60x1 and 100x1 tablets. 
Osim toga, tablete su također dostupne u blisterima djeljivim na jedinične doze za pakiranja od 30x1, 60x1 i 100x1 tableta.
Not all pack sizes may be marketed 
Na tržištu se ne moraju nalaziti sve veličine pakiranje.
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. 
Na početku liječenja ili nakon povećanja doze nuspojave, poput pospanosti, umora i omaglice, mogu se javiti češće.
In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6% for patients on placebo. 
Analizom zbirnih podataka utvrđeno je da je postotak bolesnika kod kojih je postignuto 50 %-tno ili više smanjenje od početne učestalosti djelomičnih napadaja tjedno uz konstantnu dozu (12/14 tjedana) bio 27,7% kod uzetih 1000 mg, 31,6% kod uzetih 2000 mg i 41,3% kod uzetih 3000 mg levetiracetama te 12,6% kod uzimanja placeba.
The patients were randomized to carbamazepine CR 400 - 1200 mg /day or levetiracetam 1000 - 3000 mg /day, the duration of the treatment was up to 121 weeks depending on the response. 
Bolesnici su randomizirani za dobivanje 400 -1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 - 3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents,children and infants, using the following formula (Schwartz formula): 
Klirens kreatinina u ml/min/1,73 m2 može se za mlade adolescente, djecu i dojenčad procijeniti iz vrijednosti serumskoga kreatinina (mg/dl) s pomoću sljedeće formule (Schwartzova formula):
• as an add-on to other antiepileptic medicines to treat: - partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age; - myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy - primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause). 
• kao dodatna terapija uz druge antiepileptike u liječenju: - parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata, djece i dojenčadi od prvog mjeseca života - miokloničkih napadaja (kratki, iznenadni trzaji mišića ili skupine mišića) u odraslih i adolescenata starijih od 12. godine života s juvenilnom miokloničkom epilepsijom - primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, uključujući gibitak svijesti) u odraslih i adolescenata starijih od 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koji se smatra da je genetski uvjetovan).
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. 
Levetiracetam primijenjen u dozi od 1000 mg na dan nije utjecao na farmakokinetiku oralnih kontraceptiva (etinilestradiola i levonorgestrela); endokrini pokazatelji (luteinizirajući hormon i progesteron) ostali su nepromijenjeni.
United Kingdom 
Ujedinjeno Kraljevtsvo
If you take more Levetiracetam Accord than you should The possible side effects of an overdose of Levetiracetam are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma. 
Ako uzmete više Levetiracetam Accord nego što ste trebali Moguće su nuspojave predoziranja levetiracetamom pospanost, uznemirenost, agresija, smanjena pozornost, smetnje disanja i koma.
Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg /kg bodyweight. 
Uslijed potpune i linearne apsorpcije levetiracetama, moguće je na temelju oralne doze izražene u mg/kg tjelesne težine predvidjeti razinu lijeka u plazmi.
In this study, the patients received levetiracetam as a fixed dose of 60 mg /kg/day (with twice a day dosing). 
Bolesnici su u toj studiji dobivali konstantnu dozu od 60 mg/kg/dan (doziranje dva puta na dan).
If stopping treatment, Levetiracetam Accord should be discontinued gradually to avoid an increase of seizures. 
Ako prekidate liječenje Levetiracetam Accordom, prekid mora biti postupan kako bi se izbjeglo pojačanje napadaja.
Children and adolescents - Levetiracetam Accord is not indicated in children and adolescents below 16 years on its own 
• U djece i adolescenata mlađih od 16 godina Levetiracetam Accord se ne primjenjuje samostalno
In this study, levetiracetam dose was 3000 mg /day for adults and adolescents or 60 mg /kg/day for children, given in 2 divided doses. 
Doza levetiracetama u toj studiji bila je 3000 mg na dan za odrasle i adolescente a za djecu 60 mg/kg/dan, podjeljeno na dvije doze.
Unit dose pack (perforated unit dose blister) containing 30x1, 60x1 and 100x1 tablets. 
Pakiranja djeljiva na jedinične doze (perforirani blister djeljiv na jedinične doze) sadrže 30x1, 60x1 i 100x1 tableta.
Box of 10, 20, 30, 50, 60, 100, 200 tablets 
Kutija od 10, 20, 30, 50, 60, 100, 200 tableta
In this study, patients were prescribed 20 mg /kg, 25 mg /kg, 40 mg /kg or 50 mg /kg daily dose of oral solution based on their age titration schedule. 
U toj je studiji bolesnicima propisana oralna otopina u dnevnoj dozi od 20 mg/kg, 25 mg/kg, 40 mg/kg ili 50 mg/kg prema shemi titriranja ovisnoj o dobi.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. 
Djelotvornost levetiracetama za samostalno liječenje dokazana je kod paralelnih grupa u dvostrukoslijepoj usporedbi neinferiornosti s karbamazepinom s kontroliranim otpuštanjem (CR, controlled release) na 576 bolesnika u dobi od 16 godina ili starijih s novo- ili nedavno dijagnosticiranom epilepsijom.
Following single oral dose administration (20 mg /kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. 
Nakon primjene jedne oralne doze (20 mg/kg) u djece s epilepsijom (6 do 12 godina), poluvrijeme života levetiracetama bio je 6,0 sati.
Following repeated oral dose administration (20 to 60 mg /kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. 
Nakon ponovljene primjene oralne doze (20 do 60 mg/kg/na dan) u djece s epilepsijom (4 do 12 godina), levetiracetam se brzo apsorbira.
The primary measure of effectiveness was the responder rate (percent of patients with ≥ 50% reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG. 
Primarna mjera učinkovitosti bila je stopa bolesnika s odgovorom (postotak bolesnika u kojih je dnevna prosječna učestalost napadaja smanjena za ≥ 50% u odnosu na početno stanje) određena središnjim pregledavanjem 48-satnog video EEG-a od strane ocjenjivača koji nije znao tko je dobivao placebo, a tko lijek.
Each film-coated tablet contains 250 mg, 500 mg, 750 mg or 1000 mg of levetiracetam. 
Jedna filmom obložena tableta sadrži 250 mg, 500 mg, 750 mg ili 1000 mg levetiracetama.
An oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescent (from 6 to 17 years) weighing less than 50kg and when tablets don't allow accurate dosage. 
Oralna otopina je prikladniji farmaceutski oblik za primjenu u dojenčadi i djece mlađe od 6 godina, djece i adolescenata (6-17 godina) tjelesne težine manje od 50 kg te kada se tabletama ne može postići točno doziranje.
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg /kg/day. 
Četiri studije embrio-fetalnog razvoja provedene su u kunića s dozama od 200, 600, 800, 1200 i 1800 mg/kg/dan.
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). 
Djelotvornost levetiracetama dokazana je u dvostruko-slijepoj i placebom kontroliranoj studiji u trajanju od 24 tjedna, koja je uključivala odrasle, adolescente i ograničeni broj djece s idiopatskom generaliziranom epilepsijom s primarno generaliziranim toničko-kloničkim (PGTK) napadajima kod različitih sindroma (juvenilna mioklonična epilepsija, epilepsija s apsansima dječje i juvenilne dobi ili epilepsija s grand mal napadajima kod buđenja).
• decreased blood sodium concentrations 
• snižena koncentracija natrija u krvi;
In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. 
U djece i adolescenata u dobi 4 do 16 godina povraćanje (vrlo često, 11,2%), agitacija (često, 3,4%), promjene raspoloženja (često, 2,1%), labilnost afekta (često, 1,7%), agresija (često, 8,2%), poremećaj ponašanja
A dose of 20 mg /kg/day titrating to 40 mg /kg/day for infants one month to less than six months and a dose of 25 mg /kg/day titrating to 50 mg /kg/day for infants and children 6 months to less than 4 years old, was use in this study. 
Doza od 20 mg/kg/dan titrirana je do 40 mg/kg/dan u dojenčadi u dobi od jednog do manje od 6 mjeseci, a doza od 25 mg/kg/dan titrirana je do 50 mg/kg/dan u dojenčadi i djece u dobi od 6 mjeseci do manje od 4 godine.
Levetiracetam Accord 750 mg film-coated tablets contains sunset yellow (E110) which may cause allergic reactions. 
Levetiracetam Accord 750 mg filmom obložene tablete sadrže bojilo sunset yellow (E110) koje može uzrokovati alergijske reakcije.
For children 6 years and above, Levetiracetam oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. 
U djece od 6 godina i starije, Levetiracetam oralnu otopinu treba primijenjivati za doze ispod 250 mg, doze koje nisu višekratnici od 250 mg, odnosno kada preporučeno doziranje ne može biti postignuto uzimanjem većeg broja tableta te u bolesnika koji ne mogu gutati tablete.
Suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination,anger, confusional state, panic attack, affect lability/mood swings, agitation 
Pokušaj samoubojstva, suicidalne misli, psihotični poremećaj, poremećaj ponašanja, halucinacije, srditost, konfuzno stanje, napadaj panike, labilnost afekta/promjene raspoloženja, agitacija
[140-age (years)] x weight (kg) CLcr (ml/min) = ----------------------------------------- (x 0.85 for women) 72 x serum creatinine (mg/dl) 
CLcr (ml/min) = ----------------------------------------------- (x 0,85 za žene) 72 x kreatinin u serumu (mg/dl)
Following single dose administration (20 mg /kg) of a 100 mg /ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. 
Nakon primjene jedne doze (20 mg/kg) 100 mg/ml oralne otopine u djece s epilepsijom (1 mjesec do 4 godine), levetiracetam se brzo apsorbira te je vršna koncentracija u plazmi postignuta približno 1 sat nakon uzimanja lijeka.
The tablet core ingredients are: croscarmellose sodium, povidone K-30, colloidal anhydrous silica, magnesium stearate (E470b) 
Sastojci u jezgri tablete su: umrežena karmelozanatrij, povidon K-30, bezvodni koloidni silicijev dioksid, magnezijev stearat (E470b).
Infections and infestations 
Infekcije i infestacije Nazofaringiti s
Duration of treatment - Levetiracetam Accord is used as a chronic treatment. 
• Levetiracetam Accord se koristi za kronično liječenje.
Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function 
Prilagođavanje doze za odrasle bolesnike i adolescente tjelesne težine više od 50 kg s oštećenom bubrežnom funkcijom: